Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.38 |
| ▸ | FLT1 | P17948 | 3/20 | 0.38 |
| ▸ | FLT4 | P35916 | 3/20 | 0.38 |
| ▸ | EGFR | P00533 | 8/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5226379 | 0.87 | KDR (0.41) | KDRFLT1FLT4EGFRMAPT | |
| SCHEMBL4979215 | 0.86 | ALK (0.38) | KDRFLT1FLT4PARP1 | |
| SCHEMBL4980815 | 0.82 | KDR (0.39) | KDRFLT1FLT4PARP1 | |
| SCHEMBL4976614 | 0.81 | KDR (0.35) | KDRPARP1 | |
| SCHEMBL4977078 | 0.80 | KDR (0.45) | KDRFLT1FLT4EGFRPTK2 | |
| SCHEMBL4979936 | 0.79 | EPHB4 (0.33) | KDR | |
| SCHEMBL4978000 | 0.76 | LMNA (0.41) | KDRFLT1FLT4EGFRMAPT | |
| SCHEMBL5226814 | 0.76 | KDR (0.39) | KDRFLT1FLT4EGFRPARP1 | |
| SCHEMBL4805956 | 0.73 | KDR (0.55) | KDR | |
| SCHEMBL5223878 | 0.73 | KDR (0.41) | KDRFLT1FLT4PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7338959-B2 | Diamino-pyrimidines and their use as angiogenesis inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-03-04 | — | — | US | claimed |
| US-20050234083-A1 | Diamino-pyrimidines and their use as angiogenesis inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-10-20 | — | — | US | claimed |
| US-7338959-B2 | Diamino-pyrimidines and their use as angiogenesis inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| US-20050234083-A1 | Diamino-pyrimidines and their use as angiogenesis inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234083-A1 | Diamino-pyrimidines and their use as angiogenesis inhibitors | TIE1, TEK, KDR | KDR 3/4885FLT1 5/4885FLT4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.